A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

3000 Background: Tumor PD-L1 mediates cancer immune evasion. Therefore, inhibition of PD-L1 binding represents an attractive strategy to restore tumor-specific T-cell immunity.MPDL3280A, a human mo...